Argos
My team worked with Argos from the launch of their Phase III trial to the initial data release two years later. Our responsibilities included branding the science and the MOA for the medication. Market research revealed that a patient's new immune status (ability to restart the system) was an important point to stress in the story. Resulting in The Power of Neoimmunity.. Beyond the branded messaging was a scientific visual language that helped to introduce the category of autologous cell therapy. The visual identity relied on modern typography and the presence of a stylized dendritic cell.
Brand Narrative
Fully Recognize
Argos Therapeutics is a biopharmaceutical company focused on the development of fully personalized immunotherapy for the treatment of cancer and infectious disease. For cancer, first-generation immunotherapy treatments routinely target normal or self-antigens. While these antigens may be over- expressed and seem like important targets, the immune system is incapable of selectively destroying cells expressing these normal or self-antigens because of our protection against autoimmunity.